This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Insulet Corp. (PODD) advanced 6.03% to $160.40 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&amp;P 500 Index falling 0.38% to 7,337.11 and Dow Jones Industrial Average falling 0.63% to 49,596.97.
The stock's rise snapped a three-day losing streak.
Insulet Corp. closed 54.80% short of its 52-week high of $354.88, which the company reached on November 20th.
The stock outperformed some of its competitors Thursday, as Eli Lilly &amp; Co. (LLY) fell 1.22% to $974.96, DexCom Inc. (DXCM) rose 0.91% to $60.91, and Johnson &amp; Johnson (JNJ) fell 0.94% to $222.51.
Trading volume (2.8 M) eclipsed its 50-day average volume of 1.1 M.
Data source: Dow Jones Market Data, FactSet. Data compiled May 7, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-07-26 1717ET

PODD

SBIO

LABD

Insulet Corp. (PODD) shares rose 6.03% to $160.40 on a weak trading day for the market, with the S&P 500 down 0.38% and the Dow Jones down 0.63%. This increase ended a three-day losing streak, although the stock remains 54.80% below its 52-week high of $354.88. Insulet outperformed competitors like Eli Lilly, which fell 1.22%, and Johnson & Johnson, which dropped 0.94%. Trading volume reached 2.8 million, surpassing the 50-day average of 1.1 million.

MarketWatch Automated

Insulet

ALPS Medical Breakthrough

Direxion S&P Biotech Bear 3X

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Medical Devices

SPDR S&P Health Equip

iShares Biotechnology ETF

S&P 500

Dow Jones Industrial Average

Eli Lilly

DexCom

Johnson & Johnson

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day